AlphAIAlphAI — Financial news for AI agents
247wallst.comSEP 92 min read$IDXX

Idexx Laboratories Inc (IDXX) Stock News & Articles

IDEXX Laboratories (NASDAQ: IDXX) reported Q3 earnings that exceeded EPS and revenue expectations, raising full-year guidance. The stock rose 15% following the announcement.

Original reporting
247wallst.com
Published Sep 9, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 1:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IDXX
Bullish
high confidence
Mentioned
$IDXX
Relevance
8/10
AlphAI data visualization · based on 247wallst.com
Decision brief

The 30-second read

$IDXXBullishHigh
01

Why it matters

The earnings beat validates recent product rollouts and may accelerate adoption of IDXX's diagnostic platforms.

02

Market read

Earnings surprise drives immediate price action and may set a bullish tone for the animal health sector.

03

What to watch

Potential supply‑chain constraints or regulatory scrutiny could temper upside.

Relevance 8/10Novelty 8/10Timing: after‑hours reaction

Background

IDEXX reported Q3 2026 results, beating expectations and lifting its FY outlook, prompting a sharp stock rally.

Company-level read

Ticker impact

$IDXXBullishHigh confidence
Context

IDEXX Laboratories jumped 15% after reporting Q3 earnings beat EPS and revenue expectations and raising full‑year guidance.

Expected impact

Potential continuation of the rally, with upside to $150‑$160 in the near term.

Evidence & confidence

Double‑digit price move on fresh earnings data and guidance lift indicates new buying pressure.

Market effects

Sector

Positive signal for the animal health and diagnostics sector, may lift peers like Zoetis.

Regional

U.S. healthcare and biotech stocks could see modest gains.

Global

Limited to U.S. markets but may influence global veterinary supply chains.

Counterpoint

What could challenge this read

Investors may question sustainability of the jump if guidance is modest relative to peers.

Key entities

  • Company
    IDEXX Laboratories Inc

    Veterinary diagnostics and software provider.

Read at source← All news

Related articles

SEP 5
$IDXXHighAI 8/10

Stronger Q2 Results And Raised 2026 Outlook Could Be A Game Changer For IDEXX Laboratories (IDXX)

IDEXX Laboratories (IDXX) reported Q2 2026 results exceeding earnings estimates, raising its full-year 2026 outlook. Key growth came from the Companion Animal Group, with improved margins. Management projects $5.7B revenue and $1.5B earnings by 2029, an 32% upside from current price. Analysts' views vary, with bearish estimates at $5.5B revenue and $1.5B earnings by 2029.

simplywall.st3 min
AUG 27
$IDXXHighAI 8/10

Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?

IDEXX Laboratories (IDXX), a global leader in animal health diagnostics, reported Q2 2026 revenue of $1.22B (up 9.7% YoY) and EPS of $4.07 (up 15.3%). The company raised its full-year outlook. Analysts have a 'Moderate Buy' consensus, with a mean price target of $718.14, suggesting 30.6% upside. IDXX stock is down 14.2% over 52 weeks, underperforming the S&P 500 and healthcare sector.

yahoo.com2 min
AUG 11
$IDXXHighAI 9/10

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.

yahoo.com7 min
AUG 6
$IDXXMedAI 8/10

IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary

IDEXX Laboratories reported Q2 2026 results driven by 10.3% organic growth in CAG Diagnostics recurring revenue, while U.S. same-store clinical visits fell 1.3%. Management raised full-year organic revenue growth guidance to 8.5% to 9.7% despite a $15 million FX headwind and expects U.S. visits to decline 1.5% in H2. Operating margin rose 110 bps.

yahoo.com7 min